Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours.

Toosi BM, El Zawily A, Truitt L, Shannon M, Allonby O, Babu M, DeCoteau J, Mousseau D, Ali M, Freywald T, Gall A, Vizeacoumar FS, Kirzinger MW, Geyer CR, Anderson DH, Kim T, Welm AL, Siegel P, Vizeacoumar FJ, Kusalik A, Freywald A.

Oncogene. 2018 Apr 27. doi: 10.1038/s41388-018-0228-x. [Epub ahead of print]

PMID:
29700392
2.

NetH2pan: A Computational Tool to Guide MHC Peptide Prediction on Murine Tumors.

DeVette CI, Andreatta M, Bardet W, Cate SJ, Jurtz VI, Jackson KW, Welm AL, Nielsen M, Hildebrand WH.

Cancer Immunol Res. 2018 Apr 3. doi: 10.1158/2326-6066.CIR-17-0298. [Epub ahead of print]

PMID:
29615400
3.

X-Ray of Excised Cancerous Breast Tissue Does Not Affect Clinical Biomarker Expression.

Lloyd IE, Welm AL, DeRose Y, Neumayer LA, Kohan JL, Malmberg EM, Salama ME, Factor RE.

Appl Immunohistochem Mol Morphol. 2017 Feb 9. doi: 10.1097/PAI.0000000000000454. [Epub ahead of print]

PMID:
28187031
4.

RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis.

Andrade K, Fornetti J, Zhao L, Miller SC, Randall RL, Anderson N, Waltz SE, McHale M, Welm AL.

Sci Transl Med. 2017 Jan 25;9(374). pii: eaai9338. doi: 10.1126/scitranslmed.aai9338.

5.

RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers.

Faham N, Welm AL.

Cold Spring Harb Symp Quant Biol. 2016;81:177-188. doi: 10.1101/sqb.2016.81.031377. Epub 2017 Jan 5. Review.

PMID:
28057847
6.

A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds.

Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW, Tufegdzic-Vidakovic A, Sammut SJ, Jones L, Provenzano E, Baird R, Eirew P, Hadfield J, Eldridge M, McLaren-Douglas A, Barthorpe A, Lightfoot H, O'Connor MJ, Gray J, Cortes J, Baselga J, Marangoni E, Welm AL, Aparicio S, Serra V, Garnett MJ, Caldas C.

Cell. 2016 Sep 22;167(1):260-274.e22. doi: 10.1016/j.cell.2016.08.041. Epub 2016 Sep 15.

7.

Plasma exosome microRNAs are indicative of breast cancer.

Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC, Ding WQ.

Breast Cancer Res. 2016 Sep 8;18(1):90. doi: 10.1186/s13058-016-0753-x.

8.

Short-form Ron is a novel determinant of ovarian cancer initiation and progression.

Moxley KM, Wang L, Welm AL, Bieniasz M.

Genes Cancer. 2016 May;7(5-6):169-81. doi: 10.18632/genesandcancer.109.

9.

Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.

Giró-Perafita A, Palomeras S, Lum DH, Blancafort A, Viñas G, Oliveras G, Pérez-Bueno F, Sarrats A, Welm AL, Puig T.

Clin Cancer Res. 2016 Sep 15;22(18):4687-97. doi: 10.1158/1078-0432.CCR-15-3133. Epub 2016 Apr 22.

10.

Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.

Bieniasz M, Radhakrishnan P, Faham N, De La O JP, Welm AL.

Clin Cancer Res. 2015 Dec 15;21(24):5588-600. doi: 10.1158/1078-0432.CCR-14-3283. Epub 2015 Aug 19.

11.

Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP.

Shen L, O'Shea JM, Kaadige MR, Cunha S, Wilde BR, Cohen AL, Welm AL, Ayer DE.

Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):5425-30. doi: 10.1073/pnas.1501555112. Epub 2015 Apr 13.

12.

Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma.

Chaturvedi A, Hoffman LM, Jensen CC, Lin YC, Grossmann AH, Randall RL, Lessnick SL, Welm AL, Beckerle MC.

Mol Biol Cell. 2014 Sep 15;25(18):2695-709. doi: 10.1091/mbc.E14-01-0007. Epub 2014 Jul 23.

13.

Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response.

Sikora MJ, Cooper KL, Bahreini A, Luthra S, Wang G, Chandran UR, Davidson NE, Dabbs DJ, Welm AL, Oesterreich S.

Cancer Res. 2014 Mar 1;74(5):1463-74. doi: 10.1158/0008-5472.CAN-13-2779. Epub 2014 Jan 14.

14.

The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming.

Cunha S, Lin YC, Goossen EA, DeVette CI, Albertella MR, Thomson S, Mulvihill MJ, Welm AL.

Cell Rep. 2014 Jan 16;6(1):141-54. doi: 10.1016/j.celrep.2013.12.010. Epub 2014 Jan 2.

15.

RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses.

Eyob H, Ekiz HA, Welm AL.

Oncoimmunology. 2013 Sep 1;2(9):e25670. Epub 2013 Aug 14.

16.

Survivin promotion of melanoma metastasis requires upregulation of α5 integrin.

McKenzie JA, Liu T, Jung JY, Jones BB, Ekiz HA, Welm AL, Grossman D.

Carcinogenesis. 2013 Sep;34(9):2137-44. doi: 10.1093/carcin/bgt155. Epub 2013 May 2.

17.

Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity.

Eyob H, Ekiz HA, Derose YS, Waltz SE, Williams MA, Welm AL.

Cancer Discov. 2013 Jul;3(7):751-60. doi: 10.1158/2159-8290.CD-12-0480. Epub 2013 Apr 23.

18.

Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.

Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, Wiegmans AP, Swarbrick A, Welm AL, Brown MP, Chenevix-Trench G, Lakhani SR, Khanna KK.

J Nucl Med. 2013 Jun;54(6):913-21. doi: 10.2967/jnumed.112.111534. Epub 2013 Apr 5.

19.

Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine.

DeRose YS, Gligorich KM, Wang G, Georgelas A, Bowman P, Courdy SJ, Welm AL, Welm BE.

Curr Protoc Pharmacol. 2013 Mar;Chapter 14:Unit14.23. doi: 10.1002/0471141755.ph1423s60.

20.
21.

The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma.

Chaturvedi A, Hoffman LM, Welm AL, Lessnick SL, Beckerle MC.

Genes Cancer. 2012 Feb;3(2):102-16. doi: 10.1177/1947601912457024.

22.

Blocking Fibroblast Growth Factor receptor signaling inhibits tumor growth, lymphangiogenesis, and metastasis.

Larrieu-Lahargue F, Welm AL, Bouchecareilh M, Alitalo K, Li DY, Bikfalvi A, Auguste P.

PLoS One. 2012;7(6):e39540. doi: 10.1371/journal.pone.0039540. Epub 2012 Jun 25.

23.

Mouse models of breast cancer metastasis to bone.

Kretschmann KL, Welm AL.

Cancer Metastasis Rev. 2012 Dec;31(3-4):579-83. doi: 10.1007/s10555-012-9378-4. Review.

PMID:
22706780
24.

Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells.

Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RW, Ahuja N, Brock MV, Stearns V, Feller-Kopman D, Yarmus LB, Lin YC, Welm AL, Issa JP, Minn I, Matsui W, Jang YY, Sharkis SJ, Baylin SB, Zahnow CA.

Cancer Cell. 2012 Mar 20;21(3):430-46. doi: 10.1016/j.ccr.2011.12.029.

25.

On the shoulders of giants: a historical perspective of unique experimental methods in mammary gland research.

Smith BA, Welm AL, Welm BE.

Semin Cell Dev Biol. 2012 Jul;23(5):583-90. doi: 10.1016/j.semcdb.2012.03.005. Epub 2012 Mar 9. Review.

26.

Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase.

Liu X, Zhao L, Derose YS, Lin YC, Bieniasz M, Eyob H, Buys SS, Neumayer L, Welm AL.

Genes Cancer. 2011 Jul;2(7):753-62. doi: 10.1177/1947601911421924.

27.

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes.

DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm AL.

Nat Med. 2011 Oct 23;17(11):1514-20. doi: 10.1038/nm.2454.

28.

Netrin-4 activates endothelial integrin {alpha}6{beta}1.

Larrieu-Lahargue F, Welm AL, Thomas KR, Li DY.

Circ Res. 2011 Sep 16;109(7):770-4. doi: 10.1161/CIRCRESAHA.111.247239. Epub 2011 Jul 28.

29.

Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4.

Powers MA, Fay MM, Factor RE, Welm AL, Ullman KS.

Cancer Res. 2011 Aug 15;71(16):5579-87. doi: 10.1158/0008-5472.CAN-11-0458. Epub 2011 Jun 23.

30.
31.

A dominant mutant allele of the ING4 tumor suppressor found in human cancer cells exacerbates MYC-initiated mouse mammary tumorigenesis.

Kim S, Welm AL, Bishop JM.

Cancer Res. 2010 Jun 15;70(12):5155-62. doi: 10.1158/0008-5472.CAN-10-0425. Epub 2010 May 25.

32.

Netrin-4 induces lymphangiogenesis in vivo.

Larrieu-Lahargue F, Welm AL, Thomas KR, Li DY.

Blood. 2010 Jul 1;115(26):5418-26. doi: 10.1182/blood-2009-11-252338. Epub 2010 Apr 20.

33.

HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype.

Gilbert PM, Mouw JK, Unger MA, Lakins JN, Gbegnon MK, Clemmer VB, Benezra M, Licht JD, Boudreau NJ, Tsai KK, Welm AL, Feldman MD, Weber BL, Weaver VM.

J Clin Invest. 2010 May;120(5):1535-50. doi: 10.1172/JCI39534. Epub 2010 Apr 12.

34.

The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling.

Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Barón AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, Schiemann WP, Ford HL.

J Clin Invest. 2009 Sep;119(9):2678-90. doi: 10.1172/JCI37815. Epub 2009 Aug 24.

35.

Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition.

McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL, Ford HL.

J Clin Invest. 2009 Sep;119(9):2663-77. doi: 10.1172/JCI37691. Epub 2009 Aug 24.

36.

Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers.

Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM.

Clin Cancer Res. 2009 Apr 1;15(7):2311-22. doi: 10.1158/1078-0432.CCR-08-2533. Epub 2009 Mar 24.

37.

TGFbeta primes breast tumor cells for metastasis.

Welm AL.

Cell. 2008 Apr 4;133(1):27-8. doi: 10.1016/j.cell.2008.03.012.

38.

Lentiviral transduction of mammary stem cells for analysis of gene function during development and cancer.

Welm BE, Dijkgraaf GJ, Bledau AS, Welm AL, Werb Z.

Cell Stem Cell. 2008 Jan 10;2(1):90-102. doi: 10.1016/j.stem.2007.10.002.

39.

The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans.

Welm AL, Sneddon JB, Taylor C, Nuyten DS, van de Vijver MJ, Hasegawa BH, Bishop JM.

Proc Natl Acad Sci U S A. 2007 May 1;104(18):7570-5. Epub 2007 Apr 24.

40.

MET and MYC cooperate in mammary tumorigenesis.

Welm AL, Kim S, Welm BE, Bishop JM.

Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4324-9. Epub 2005 Feb 28.

42.

Calreticulin interacts with C/EBPalpha and C/EBPbeta mRNAs and represses translation of C/EBP proteins.

Timchenko LT, Iakova P, Welm AL, Cai ZJ, Timchenko NA.

Mol Cell Biol. 2002 Oct;22(20):7242-57.

43.

C/EBPalpha is required for proteolytic cleavage of cyclin A by calpain 3 in myeloid precursor cells.

Welm AL, Timchenko NA, Ono Y, Sorimachi H, Radomska HS, Tenen DG, Lekstrom-Himes J, Darlington GJ.

J Biol Chem. 2002 Sep 13;277(37):33848-56. Epub 2002 Jul 8.

44.

RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1.

Timchenko NA, Cai ZJ, Welm AL, Reddy S, Ashizawa T, Timchenko LT.

J Biol Chem. 2001 Mar 16;276(11):7820-6. Epub 2000 Dec 21.

45.
46.
47.

C/EBPalpha regulates generation of C/EBPbeta isoforms through activation of specific proteolytic cleavage.

Welm AL, Timchenko NA, Darlington GJ.

Mol Cell Biol. 1999 Mar;19(3):1695-704.

Supplemental Content

Support Center